论文信息 - Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19 - 字舞流文

Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19

G. Varoquaux | O. Grisel | A. Burgun | N. Griffon | F. Carrat | J. Champ | J. Vie | N. Garcelon | A. Neuraz | D. Wassermann | B. Rance | M. Wack | M. Mamzer | E. Zapletal | P. Ancel | Nina Orlova | C. Daniel | Vincent Benoit | Romain Bey | N. Paris | Patricia Serre | Julien Dubiel | M. Hilka | A. Jannot | S. Bréant | J. Leblanc | M. Bernaux | Arnaud Sandrin | E. Salamanca | P. Martel | Damien Leprovost | T. Moreau | A. Mensch | C. Caucheteux | N. Beeker | F. Hemery | J. Treluyer | A. Bourmaud | J. Lambert | Xavier Tannier | E. Polard | D. van Gysel | C. Hassen-Khodja | R. Layese | S. Cormont | Loïc Estève | Marie Frank | Alexandre Gramfort | G. Lemaître | I. Lerner | L. Chouchana | Pierre-Yves Alain Nathanaël Vincent Mélodie Ali Romain Aurélie Ancel Bauchet Beeker Benoit Bernaux B | A. Bauchet | A. Bellamine | Catherine Ducloas | Martin Guilbaud | Léo Lebouter | Kankoe Levi Sallah | A. Maire | Hélène Ravera | Antoine Rozès | Perceval Wajsburt | M. Frank | Nicolas Garcelon | Antoine Rozes | Julien Champ | Alain Bauchet | Richard Layese | R. Bey | Stéphane Bréant | Jill-Jênn Vie

[1] Kevin Bretonnel Cohen,et al. Natural Language Processing for Rapid Response to Emergent Diseases: Case Study of Calcium Channel Blockers and Hypertension in the COVID-19 Pandemic , 2020, Journal of medical Internet research.

[2] L. Mantovani,et al. Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis , 2020, Heart.

[3] C. Torp‐Pedersen,et al. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. , 2020, JAMA.

[4] P. Serruys,et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study , 2020, European heart journal.

[5] L. Rodríguez-Mañas,et al. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study , 2020, The Lancet.

[6] A. Troxel,et al. Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19 , 2020, The New England journal of medicine.

[7] Jian Chen,et al. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. , 2020, JAMA cardiology.

[8] J. Narula,et al. Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System , 2020, Journal of the American College of Cardiology.

[9] Marc A Pfeffer,et al. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 , 2020, The New England journal of medicine.

[10] Ke Ma,et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study , 2020, BMJ.

[11] D. Gurwitz. Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics , 2020, Drug development research.

[12] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[13] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[14] S. Xiao,et al. Porcine deltacoronavirus (PDCoV) modulates calcium influx to favor viral replication , 2019, Virology.

[15] Guillaume Lample,et al. Neural Architectures for Named Entity Recognition , 2016, NAACL.

[16] Valentino Braitenberg,et al. Neural Architecture , 1988, NIPS.